Keywords
NIHSS
Fibrinolytic treatment
Severe sequelae
How to Cite
Abstract
Introduction: Stroke is the third leading cause of death and the leading cause of disability in Argentina. Eighty per cent of strokes are ischaemic. Stroke requires the use of a standardised scale, such as the National Institute of Health Stroke Scale (NIHSS), in order to document possible deficits and their severity, as well as to make decisions regarding the treatment to be administered. Objective: To calculate the frequency with which the NIHSS scale is used within the window period as a method of diagnosing ischemic stroke in patients attending the Eva Perón Hospital (Granadero Baigorria, Santa Fe) in 2023. Materials and methods: A quantitative, observational study was conducted with a descriptive, cross-sectional, retrospective design. The population consisted of all patients of both sexes diagnosed with ischaemic stroke who attended a post-hospitalisation check-up at the outpatient clinic of the neurology department of Eva Perón Hospital. Patients over 18 years of age diagnosed with ischaemic stroke during the study period were included. The medical records of patients diagnosed with ischaemic stroke were used as a secondary data source. Results: A sample of 20 patients diagnosed with ischaemic stroke was analysed. Of these, only 30% were diagnosed within the therapeutic window, but only 20% of the total number of patients were classified based on the NIHss scale at admission. Seventy per cent of patients had an NIHss score between 4 and 24 points, which allowed them to be classified as possible candidates for fibrinolytic treatment, but only 10% of patients were able to access this treatment and 85% were left with serious sequelae. Conclusions: The NIHss scale is rarely used as a diagnostic method for ischaemic stroke within a window period. The lack of this data at the appropriate time hinders decision-making and makes it less likely that fibrinolytic treatment will be administered at the right time and that patients will have a better outcome.
References
1. Alonzo C, Ameriso S, Atallah AM, Cirio JJ, Zurrú MC. Consenso de diagnóstico y tratamiento agudo del accidente cerebrovascular isquémico. Rev Argent Cardiol. 2012;80(5):1-16. Disponible en: [http://www.scielo.org.ar/pdf/rac/v80n5/v80n5a14.pdf](http://www.scielo.org.ar/pdf/rac/v80n5/v80n5a14.pdf)
2. Arauz A, Ruiz-Franco A. Enfermedad vascular cerebral. Rev Fac Med UNAM. 2012;55(3):1-16. Disponible en: [https://www.medigraphic.com/pdfs/facmed/un-2012/un123c.pdf](https://www.medigraphic.com/pdfs/facmed/un-2012/un123c.pdf)
3. Atallah A, Fustinoni O, Zurru M, Beigelman R, Cirio J, Ameriso S, et al. Identifying barriers in acute stroke therapy in Argentina: ARENAS Registry. Neurology. 2014;82(10 Suppl):2-14. Disponible en: [https://n.neurology.org/content/82/10_Supplement/P2.014](https://n.neurology.org/content/82/10_Supplement/P2.014)
4. Bahit MC, Coppola ML, Riccio PM, Cipriano LE, Roth GA, Lopes RD, et al. First-ever stroke and transient ischemic attack incidence and 30-day case-fatality rates in Argentina. Stroke. 2016;47(6):1640-2. doi:10.1161/STROKEAHA.116.013637
5. Casaubon LK, Boulanger JM, Glasser E, Blacquiere D, Boucher S, Brown K, et al; Heart and Stroke Foundation of Canada Canadian Stroke Best Practices Advisory Committee. Canadian stroke best practice recommendations: acute inpatient stroke care guidelines, update 2015. Int J Stroke. 2016;11(2):239-52. doi:10.1177/1747493015622461
6. Castillo J, Luna A, Rodríguez-Yáñez M, Ugarriza I, Zarranz JJ. Enfermedades vasculares cerebrales. En: Zarranz JJ, editor. Neurología. Barcelona: Elsevier; 2018. p.301-57.
7. Clementti P, Wajser B, Szulman C, Olleta L, Vidal L, Velasquez M, et al. Tratamiento con alteplasa en infarto cerebral en la unidad de ictus (Registro TAICUS). Rev Fed Argent Cardiol. 2008;37(1):41-7. Disponible en: [https://www.researchgate.net/publication/242536263](https://www.researchgate.net/publication/242536263)
8. Cummock JS, Wong KK, Volpi JJ, Wong ST. Reliability of the NIH Stroke Scale between emergency room and neurology physicians. Cureus. 2023;15(4):1-7. Disponible en: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183481](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183481)
9. Diaz A, Roldan Gerschcovich E, Diaz AA, Antía F, Gonorazky S. Seasonal variations and trends in stroke hospitalizations and mortality. J Stroke Cerebrovasc Dis. 2013;22(7):66-9. doi:10.1016/j.jstrokecerebrovasdis.2012.04.007
10. Duncan PW, Zorowitz R, Bates B, Choi JY, Glasberg JJ, Graham GD, et al. Management of adult stroke rehabilitation care: a clinical practice guideline. Stroke. 2005;36(9):100-43. doi:10.1161/01.STR.0000180861.54180.FF
11. Esnaola MM, Gregori L. Protocolo de manejo inicial del ataque cerebrovascular isquémico agudo. Buenos Aires: Ministerio de Salud. Disponible en: [https://bancos.salud.gob.ar](https://bancos.salud.gob.ar)
12. European Stroke Organization (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischemic stroke and transient ischemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507. doi:10.1159/000131083
13. Fonarow GC, Saver JL, Smith EE, Broderick JP, Kleindorfer DO, Sacco RL, et al. Relationship of NIH Stroke Scale to 30-day mortality. J Am Heart Assoc. 2012;1(1):42-50. doi:10.1161/JAHA.111.000034
14. Garavelli F, Ghelfi AM, Kilstein JG. Utilidad del score NIHSS como predictor de complicaciones intrahospitalarias. Med Clin (Barc). 2021;157(9):434-7. doi:10.1016/j.medcli.2020.07.034
15. Goldstein LB. Enfermedad cerebrovascular isquémica. En: Goldman L, Schafer A, editores. Goldman-Cecil. Tratado de medicina interna. Elsevier; 2021.
16. González Piña R, Landínez Martínez D. Epidemiología, etiología y clasificación de la enfermedad vascular cerebral. Arch Med (Manizales). 2016;16(2):495-507. Disponible en: [https://revistasum.umanizales.edu.co](https://revistasum.umanizales.edu.co)
17. Hénon H, Godofredo O, Leys D, Mounhier-Vehier F, Lucas C, Rondepierre P, et al. Early predictors of death and disability after acute cerebral ischemic event. Stroke. 1995;26(3):392-8. doi:10.1161/01.STR.26.3.392
18. Huiling Z, Yifan Q, Suing G, Kai Y, Ruijun J, Guangbo Z, et al. Correlation analysis of TOAST classification and NIHSS score. Rev Assoc Med Bras. 2022;68(1):44-9. doi:10.1590/1806-9282.20210413
19. Hung-Ming W, I-Hui L, Chao-Bao L, Chih-Ping H, Yung-Yang L. Clinical CT-mismatch as marker of thrombolysis candidacy. PLoS One. 2021;16(4):1-11. Disponible en: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087040](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087040)
20. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for early management of acute ischemic stroke. Stroke. 2013;44(3):870-947. doi:10.1161/STR.0b013e318284056a
21. Johnston KC, Connors AF Jr, Wagner DP, Knaus WA, Wang X, Harley EC Jr. Predicting outcome after acute ischemic stroke. Stroke. 2000;31(2):448-55. doi:10.1161/01.STR.31.2.448
22. Kleindorfer D, Towfighi A, Chaturvedi S, Cockroft MK, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for prevention of stroke. Stroke. 2021;52(7):364-467. doi:10.1161/STR.0000000000000375
23. Melcon MC, Melcon MO. Prevalence of stroke in Argentine community. Neuroepidemiology. 2006;27(2):81-8. doi:10.1159/000094978
24. Mistry EA, Yeatts S, De Havenon A, Mehta T, Arora N, De Los Rios La Rosa F, et al. Predicting 90-day outcome after thrombectomy. Stroke. 2021;52(8):2547-53. doi:10.1161/STROKEAHA.120.032487
25. Monaster Villalonga J, Alvarez-Sabín J. La escala NIHSS y su adaptación al español. Neurología. 2006;21(4):192-202.
26. Nedeltchev K, Karameshev A, Haefeli T, Brekenfeld C, Meier N, Remonda L, et al. Predictors of early mortality after ischemic stroke. Swiss Med Wkly. 2010;140(17-18):254-9. doi:10.4414/smw.2010.12919
27. Pigretti SG, Alet MJ, Mamani CE, Alonzo C, Aguilar M, Ameriso S, et al. Consenso sobre accidente cerebrovascular isquémico agudo. Medicina (B Aires). 2019;79(Supl II):1-46. Disponible en: [https://sna.org.ar](https://sna.org.ar)
28. Rooper AH, Samuels MA, Klein JP, Prasad S. Adams y Victor. Principios de la neurología. 11ª ed. McGraw-Hill; 2020.
29. Sposato LA, Esnaola MM, Zamora R, Zurrú MC, Fustinoni O, Saposnik G, et al. Quality of ischemic stroke care in Argentina. Stroke. 2008;39(11):3036-41. doi:10.1161/STROKEAHA.108.521062
30. Villalobos E, Barnes SR, Qureshi IA, Cruz-Flores S, Maud A, Rodriguez GJ. Spanish version of the NIH Stroke Scale. J Vasc Interv Neurol. 2017;9(3):1-6. Disponible en: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317283](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317283)
31. Wardlaw J, Brazzelli M, Miranda H, Chappell F, McNamee P, Scotland G, et al. Cost-effectiveness of MRI in TIA and minor stroke. Health Technol Assess. 2014;18(27):1-365. doi:10.3310/hta18270
32. Weimar C, König IR, Kraywinkel K, Ziegler A, Diener HC. Age and NIHSS as predictors of outcome. Stroke. 2003;35(1):158-62. doi:10.1161/01.STR.0000106761.94985.8b
33. Alamowitch S, Turc G, Palaiodimou L, Bivard A, Cameron A, De Marchis GM, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. European Stroke Journal 2023;8:8–54. https://doi.org/10.1177/23969873221150022.
34. Chen H-S, Cui Y, Li X-Q, Wang X-H, Ma Y-T, Zhao Y, et al. Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke: The RICAMIS Randomized Clinical Trial. JAMA 2022;328:627–36. https://doi.org/10.1001/jama.2022.13123.
35. Chen H-S, Cui Y, Zhou Z-H, Zhang H, Wang L-X, Wang W-Z, et al. Dual Antiplatelet Therapy vs Alteplase for Patients with Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. JAMA 2023;329:2135–44. https://doi.org/10.1001/jama.2023.7827.
36. Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, et al. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. New England Journal of Medicine 2024;390:1745–55. https://doi.org/10.1056/NEJMoa2313040.
37. Costalat V, Jovin TG, Albucher JF, Cognard C, Hénon H, Nouri N, et al. Trial of Thrombectomy for Stroke with a Large Infarct of Unrestricted Size. New England Journal of Medicine 2024;390:1677–89. https://doi.org/10.1056/NEJMoa2314063.
38. Deng G, Xiao J, Yu H, Chen M, Shang K, Qin C, et al. Predictors of futile recanalization after endovascular treatment in acute ischemic stroke: a meta-analysis. Journal of NeuroInterventional Surgery 2022;14:881–5. https://doi.org/10.1136/neurintsurg-2021-017963.
39. Fischer U, Koga M, Strbian D, Branca M, Abend S, Trelle S, et al. Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. New England Journal of Medicine 2023;388:2411–21. https://doi.org/10.1056/NEJMoa2303048.
40. Gong P, Liu Y, Gong Y, Chen G, Zhang X, Wang S, et al. The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke. Journal of Neuroinflammation 2021;18. https://doi.org/10.1186/s12974-021-02090-6.
41. Jadhav AP, Desai SM, Jovin TG. Indications for Mechanical Thrombectomy for Acute Ischemic Stroke: Current Guidelines and Beyond. Neurology 2021;97:S126–36. https://doi.org/10.1212/WNL.0000000000012801.
42. Kvistad CE, Naess H, Helleberg BH, Idicula T, Hagberg G, Nordby LM, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. The Lancet Neurology 2022;21:511–9. https://doi.org/10.1016/S1474-4422(22)00124-7.
43. Li G, Lin Y, Yang J, Anderson CS, Chen C, Liu F, et al. Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke. New England Journal of Medicine 2024;390:1862–72. https://doi.org/10.1056/NEJMoa2314741.
44. Liebeskind DS, Saber H, Xiang B, Jadhav AP, Jovin TG, Haussen DC, et al. Collateral Circulation in Thrombectomy for Stroke after 6 to 24 Hours in the DAWN Trial. Stroke 2022;29:742–8. https://doi.org/10.1161/STROKEAHA.121.034471.
45. Lin K-B, Fan F-H, Cai M-Q, Yu Y, Fu C-L, Ding L-Y, et al. Systemic immune inflammation index and system inflammation response index are potential biomarkers of atrial fibrillation among the patients presenting with ischemic stroke. European Journal of Medical Research 2022;27. https://doi.org/10.1186/s40001-022-00733-9.
46. Mazurek MH, Cahn BA, Yuen MM, Prabhat AM, Chavva IR, Shah JT, et al. Portable, bedside, low-field magnetic resonance imaging for evaluation of intracerebral hemorrhage. Nature Communications 2021;12. https://doi.org/10.1038/s41467-021-25441-6.
47. Oldgren J, Åsberg S, Hijazi Z, Wester P, Bertilsson M, Norrving B. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy after Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation 2022;146:1056–66. https://doi.org/10.1161/CIRCULATIONAHA.122.060666.
48. Olthuis SGH, Pirson FAV, Pinckaers FME, Hinsenveld WH, Nieboer D, Ceulemans A, et al. Endovascular treatment versus no endovascular treatment after 6–24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. The Lancet 2023;401:1371–80. https://doi.org/10.1016/S0140-6736(23)00575-5.
49. Pérez de la Ossa N, Abilleira S, Jovin TG, Garcia-Tornel A, Jiménez X, Urra X, et al. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients with Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial. JAMA 2022;327:1782–94. https://doi.org/10.1001/jama.2022.4404.
50. Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Ga̧secki D, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. European Stroke Journal 2021;6:XLVIII–LXXXIX. https://doi.org/10.1177/23969873211012133.
51. Shah VA, Thompson RE, Yenokyan G, Acosta JN, Avadhani R, Dlugash R, et al. One-Year Outcome Trajectories and Factors Associated with Functional Recovery among Survivors of Intracerebral and Intraventricular Hemorrhage with Initial Severe Disability. JAMA Neurology 2022;79:856–68. https://doi.org/10.1001/jamaneurol.2022.1991.
52. Shoamanesh A, Mundl H, Smith EE, Masjuán J, Milanov I, Hirano T, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet 2022;400:997–1007. https://doi.org/10.1016/S0140-6736(22)01588-4.
53. Toyoda K, Yoshimura S, Nakai M, Koga M, Sasahara Y, Sonoda K, et al. Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes. JAMA Neurology 2022;79:61–9. https://doi.org/10.1001/jamaneurol.2021.4346.
54. van der Steen W, van de Graaf RA, Chalos V, Lingsma HF, van Doormaal P-J, Coutinho JM, et al. Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. The Lancet 2022;399:1059–69. https://doi.org/10.1016/S0140-6736(22)00014-9.
55. Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. The Lancet 2023;401:645–54. https://doi.org/10.1016/S0140-6736(22)02600-9.
56. Xiong Y, Wakhloo AK, Fisher M. Advances in acute ischemic stroke therapy. Circulation Research 2022;130:1230–51. https://doi.org/10.1161/CIRCRESAHA.121.319948.
57. Xu K, Gao X, Xia G, Chen M, Zeng N, Wang S, et al. Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn. Gut 2021;70:1486–94. https://doi.org/10.1136/gutjnl-2020-323263.
58. Yang P, Song L, Zhang Y, Zhang X, Chen X, Li Y, et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial. The Lancet 2022;400:1585–96. https://doi.org/10.1016/S0140-6736(22)01882-7.
59. Yoshimura S, Sakai N, Yamagami H, Uchida K, Beppu M, Toyoda K, et al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. New England Journal of Medicine 2022;386:1303–13. https://doi.org/10.1056/NEJMoa2118191.
60. Brugnara G, Neuberger U, Mahmutoglu MA, Foltyn M, Herweh C, Nagel S, et al. Multimodal Predictive Modeling of Endovascular Treatment Outcome for Acute Ischemic Stroke Using Machine-Learning. Stroke 2020;51:3541–51. https://doi.org/10.1161/STROKEAHA.120.030287.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 German Amadeo Erhardt, Mónica y Taborda (Author)